Steve Bloor
CEO, Videregen


Videregen is a clinical-stage regenerative medicine company with a proprietary cell-based tissue engineering technology platform developing personalised, curative therapies for a range of severely debilitating, chronic diseases where there are no current gold standard treatments.
The Company’s leading programmes are focused on the development of a portfolio of orphan medicinal products with a lead indication targeting life threatening complications following lung surgery.

Matchmaking Information

Processing. Please wait.